MMS19

Across TCGA pan-cancer cohorts, MMS19 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MMS19 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MMS19 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MMS19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCEC and LUSC are the cancer types where MMS19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.843	0.627	.005	14	view →
LUSC	DFS	Median	All	1.000	0.372	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MMS19–UCEC (DFS)

Open the UCEC breakdown →